Yung Zip Chemical Ind. Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019
March 24, 2020 at 07:16 pm
Share
Yung Zip Chemical Ind. Co., Ltd. announced earnings results for the full year ended December 31, 2019. For the full year, the company announced sales was TWD 416.837 million compared to TWD 357.090 million a year ago. Operating income was TWD 21.925 million compared to operating loss of TWD 21.823 million a year ago. Net income was TWD 31.319 million compared to net loss of TWD 14.957 million a year ago. Basic earnings per share was TWD 0.74 compared to basic loss per share of TWD 0.35 a year ago.
YUNG ZIP CHEMICAL IND. CO., LTD. is a Taiwan-based company principally engaged in the manufacturing and trading of pharmaceutical ingredient products. Its diclofenac sodium (DCS) is used for the treatment of rheumatoid arthritis, bursitis and inflammation. The acyclovir (ACV) is used for the treatment of herpes virus infections. The miconazole nitrate (MCN) is used for the treatment of yeast infection. The sodium starch glycolate (SSG) is used as disintegrant in pharmaceutical preparation. The Clonidine hydrochloride (CLD) is used for the treatment of hypertension. The Company mainly distributes its products in domestic market and overseas markets, including the United States of America (the USA), Thailand, Indonesia and the Philippines.
YUNG ZIP CHEMICAL IND. CO., LTD. 
